These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Left ventricular dysfunction: causes, natural history, and hopes for reversal. Armstrong PW Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i15-7:discussion i50. PubMed ID: 10956313 [No Abstract] [Full Text] [Related]
44. Natural history of end-stage LV dysfunction: has it improved from the classic Franciosa and Cohn Graph? Jacoby D; Albajrami O; Bellumkonda L Cardiol Clin; 2011 Nov; 29(4):485-95. PubMed ID: 22062195 [TBL] [Abstract][Full Text] [Related]
45. Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. Dzau VJ; Pratt R; Gibbons GH Drugs; 1994; 47 Suppl 4():1-13. PubMed ID: 7523057 [TBL] [Abstract][Full Text] [Related]
48. Overview of the relationship between ischemia and congestive heart failure. Remme WJ Clin Cardiol; 2000 Jul; 23(7 Suppl 4):IV4-8. PubMed ID: 10894449 [TBL] [Abstract][Full Text] [Related]
49. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. Francis GS J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S16-21. PubMed ID: 9731691 [TBL] [Abstract][Full Text] [Related]
50. Lifestyle and dietary modification for prevention of heart failure. Katz DL Med Clin North Am; 2004 Sep; 88(5):1295-320, xii. PubMed ID: 15331318 [TBL] [Abstract][Full Text] [Related]
52. [Treatment of cardiac insufficiency in ischemic heart disease]. Broustet JP; Douard H; Koch M; Oysel N; Massière JP Arch Mal Coeur Vaiss; 1990 Nov; 83(13):1941-8. PubMed ID: 2125413 [TBL] [Abstract][Full Text] [Related]
53. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Sigurdsson A; Swedberg K Am Heart J; 1996 Jul; 132(1 Pt 2 Su):229-34. PubMed ID: 8677861 [TBL] [Abstract][Full Text] [Related]
54. New hope for failing hearts. Schmitt BP Va Med Q; 1991; 118(2):103-5. PubMed ID: 2039775 [TBL] [Abstract][Full Text] [Related]
55. [Pathophysiology and therapeutic implications of left heart failure]. de Gevigney G; Fol S; Delahaye F Rev Med Interne; 2005 Nov; 26(11):874-84. PubMed ID: 16271807 [TBL] [Abstract][Full Text] [Related]
56. Prevention and management of chronic heart failure in patients at risk. Dei Cas L; Metra M; Nodari S; Dei Cas A; Gheorghiade M Am J Cardiol; 2003 May; 91(9A):10F-17F. PubMed ID: 12729847 [TBL] [Abstract][Full Text] [Related]
57. Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Shah KB; Gottlieb SS Curr Heart Fail Rep; 2004 Dec; 1(4):161-7. PubMed ID: 16036040 [TBL] [Abstract][Full Text] [Related]
58. Mechanisms of development of heart failure in the hypertensive patient. Bristow MR Cardiology; 1999; 92 Suppl 1():3-6; discussion 7-9, 20-1. PubMed ID: 10652966 [TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. Steingart RM; Liu JE; Oeffinger KC Ann Intern Med; 2014 May; 160(10):731-2. PubMed ID: 24842420 [No Abstract] [Full Text] [Related]
60. [Prevention of ischemic cardiopathy, with special reference to secondary prevention in the post-infarct period]. Greco R; Siciliano S; Gentile F; Elia L; Murena E; Forni N; Boccalatte A; Marsico F Boll Soc Ital Cardiol; 1981; 26(8):759-65. PubMed ID: 6127093 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]